Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

MariTide (maridebart cafraglutide; formerly AMG 133) hit the headlines in May after Amgen management expressed its excitement about the GLP-1 and GIP-directed bispecific antibody in its first ...

Amgen stock slouched Wednesday after an Eli Lilly executive called the company's early-stage test results for a weight-loss drug "a bit underwhelming." Please watch the video at Investors.com ...